Cyclic Materials to Invest Over USD $20M in its First Commercial Facility in the United States
23.4.2025 14:30:00 CEST | Business Wire | Press Release
Cyclic Materials, the advanced recycling company creating a circular supply chain for rare earth elements (REEs) and other critical materials, today announced it has invested over USD $20M in its first commercial facility, located in Mesa, Arizona. The new state-of-the-art facility will be the company’s first global REE recycling operation focused on the separation of permanent magnets from end-of-life products previously not recovered, using its proprietary MagCycle℠ process.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423172110/en/
Photo of Cyclic Materials' new commercial facility located in Mesa, Arizona (credit: Cyclic Materials)
As part of the company’s commitment to building a sustainable ecosystem, Cyclic Materials is establishing a feedstock supply network that will serve the entire U.S. While the company has already secured partnerships in the Southwest—a key region with an estimated 155,000 tonnes per year of end-of-life components from automotive and e-scrap metals—it is actively expanding its reach nationwide to develop a more robust and scalable supply chain.
“We are excited to begin commercial operations in the U.S. in early 2026,” said Ahmad Ghahreman, CEO and co-founder of Cyclic Materials. “We have chosen the vibrant Southwest for our first U.S. and global site to be close to feedstock that will support our mission to address the global supply-demand imbalance for rare earth materials. By developing circular supply chains, we can reduce dependence on overseas sources and secure a more stable REE supply for the future.”
Recruitment for the first hires at the Mesa facility is expected to begin in Q2 2025, to fill the over 30 jobs required to operate the plant. The new plant will help drive innovations in the electronic scrap and metal recycling industry while supporting local economic growth.
State officials welcomed the news, praising it as a major step toward economic growth and job creation in the region.
“We are proud Cyclic Materials will establish its first U.S. facility right here in Arizona,” said Governor Katie Hobbs. “This facility will create family-sustaining jobs and support thriving industries, all while advancing Arizona’s clean energy economy.”
“This facility means more good-paying jobs in Mesa and a stronger supply chain that will power everything from electric vehicles to artificial intelligence,” said Senator Mark Kelly. “Arizona is leading the way on clean energy and innovation, and this investment will make sure we build more of what we need right here.”
“Cyclic Materials' investment in Mesa is a significant win for Arizona. This new facility will not only create good-paying jobs for our community but also position Arizona as a leader in the critical rare earth element recycling industry, an important step in strengthening our economy and securing a sustainable future,” said Senator Ruben Gallego.
Local officials emphasized Cyclic Materials’ planned location in strengthening the local workforce and advancing clean energy innovation. “Investing in the circular economy is vital for Greater Phoenix to continue its development as a world-class region for companies and people,” said Greater Phoenix Economic Council President & CEO Chris Camacho. "Cyclic Materials complements the strong presence of data centers and EV manufacturers in the region, creating a more sustainable supply chain while strengthening the domestic availability of rare earth elements and other critical resources."
“We’re proud to welcome Cyclic Materials to Mesa. Their investment brings jobs to our community and positions Mesa as a hub for clean tech innovation and sustainable manufacturing,” said Mayor Mark Freeman. “This is the kind of forward-thinking industry we want to attract as we build a resilient and green economic future.”
“Cyclic Materials’ facility showcases Arizona’s global attractiveness for high-tech industries,” said Sandra Watson, President and CEO of the Arizona Commerce Authority. “With this state-of-the-art facility, Cyclic Materials will strengthen Arizona’s renewable energy ecosystem and further our leadership in emerging technologies.”
Cyclic Materials raised USD $57 million in its Series B equity round last year, backed by global industry leaders like Microsoft, Hitachi Ventures, BMW iVentures, and specialised funds ArcTern Ventures and Fifth Wall. The initial raise of USD $53 million was extended to include investments from InMotion Ventures and Amazon’s Climate Pledge Fund. Together, these investments position Cyclic Materials as a key partner for companies seeking sustainable and circular supply chain solutions, particularly in the automotive and data center industries. This move into the US underscores the critical role Cyclic Materials plays in advancing sustainable supply chains as it expands its footprint across North America with plans to establish operations in Europe.
Established in 2021, Cyclic Materials’ proprietary technologies are capable of economically and sustainably recovering critical raw materials from end-of-life electric vehicle motors, wind turbines, MRI machines, and data center electronic waste. Over the years, the company has forged strategic partnerships with key industry leaders such as Solvay, Vattenfall, Synetiq, and VACUUMSCHMELZE to recycle magnets containing REEs and establish a circular supply chain.
About Cyclic Materials
Cyclic Materials, founded in 2021, is a cleantech company building a circular supply chain for rare earth elements (REEs) and other critical materials essential to the clean energy transition. Its innovative technology transforms end-of-life products into valuable raw materials used in EVs, wind turbines, and electronics. In 2023, the company launched a commercial demo facility using its Mag-CycleSM process to recover rare earth magnets. In 2024, it opened a second facility in Kingston, Ontario, producing Mixed Rare Earth Oxide via its REEPureSM hydrometallurgical process. With demand for REE-based magnets surging, Cyclic Materials is scaling globally across North America, Europe, and Asia. Mesa, Arizona, is its first U.S. location. Learn more at cyclicmaterials.earth.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250423172110/en/
Contacts
Media
Jacquie Kane
cyclicmaterials@antennagroup.com
978-764-7840
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom